Calcitrol

Dosage for calcitriol must be highly individualized based on the patient's serum calcium levels, phosphorus levels, and parathyroid hormone (PTH) concentrations. The goal of therapy is to maintain serum calcium within the normal range while suppressing PTH.

• For Chronic Renal Dialysis: The recommended initial dose is 0.25 mcg daily. If a satisfactory response in biochemical parameters is not observed, the dosage may be increased by 0.25 mcg per day at intervals of 4 to 8 weeks. Most patients respond to doses between 0.5 mcg and 1 mcg per day. In some cases, three-times-weekly (pulse) dosing of 0.5 mcg to 3 mcg may be used during dialysis.
• For Hypoparathyroidism: The initial dose is 0.25 mcg daily, administered in the morning. If the response is inadequate, the dose may be increased at 2- to 4-week intervals. Most adults require 0.5 mcg to 2 mcg per day.
• For Predialysis CKD (Stage 3/4): The initial dose is typically 0.25 mcg per day. The dose may be increased to 0.5 mcg per day if necessary.

Calcitriol is used in pediatric patients, particularly those with hypoparathyroidism or renal osteodystrophy. Dosing is often weight-based or surface-area-based.

• Hypoparathyroidism (Children 1-5 years): The typical dose is 0.25 mcg to 0.75 mcg once daily.
• Renal Osteodystrophy (Pediatric Dialysis): Initial doses often start at 0.01 mcg/kg/day, with careful titration based on laboratory response. Pediatric use requires extreme caution and frequent monitoring of growth and bone development.

Renal Impairment

In patients with renal impairment, calcitriol is the drug of choice because it does not require renal activation. However, dose titration must be extremely cautious. If the calcium-phosphorus product (Ca x P) exceeds 55 mg²/dL², the dose should be reduced or held to prevent ectopic calcification (calcium deposits in soft tissues).

Hepatic Impairment

No specific dose adjustments are generally required for patients with liver disease, as calcitriol does not require hepatic hydroxylation. However, patients with severe cholestatic liver disease may have impaired absorption of oral calcitriol due to bile acid deficiency.

Elderly Patients

Dosing in elderly patients should be conservative, usually starting at the low end of the dosing range. This population is at higher risk for hypercalcemia and may have age-related declines in renal function that affect the clearance of calcium.

• Consistency: Take calcitriol at the same time every day to maintain steady blood levels. It can be taken with or without food, but taking it with a meal containing some fat may help absorption.
• Swallow Whole: Capsules should be swallowed whole. Do not crush or chew them. For the oral solution, use the provided calibrated dropper to ensure an accurate dose.
• Dietary Considerations: Your doctor may prescribe a specific diet (e.g., low phosphorus or high/low calcium). It is critical to adhere to these dietary restrictions, as calcitriol significantly increases the absorption of minerals from your food.
• Storage: Store at room temperature (59°F to 86°F) in a dry place. Protect the medication from light, as calcitriol is light-sensitive and can degrade if exposed to UV rays.

If you miss a dose, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and return to your regular schedule. Do not double the dose to catch up, as this significantly increases the risk of hypercalcemia.

An overdose of calcitriol can lead to life-threatening hypercalcemia (excessively high blood calcium). Symptoms of acute overdose include severe nausea, vomiting, constipation, abdominal pain, and confusion. Chronic overdose leads to calcium deposits in the kidneys (nephrocalcinosis) and blood vessels.

In the event of a suspected overdose, seek emergency medical attention immediately. Treatment typically involves immediate discontinuation of the drug, a low-calcium diet, and potentially the administration of intravenous fluids or diuretics to promote calcium excretion.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose without medical guidance, as even small changes can significantly impact your blood chemistry.

The most common side effects of calcitriol are directly related to its physiological action: increasing calcium levels. When calcium levels become slightly elevated (mild hypercalcemia), patients may experience:

• Gastrointestinal Distress: Nausea, occasional vomiting, and constipation are frequently reported. These symptoms usually occur early in treatment as the body adjusts to the medication.
• Dry Mouth and Thirst: A persistent feeling of dry mouth (xerostomia) or increased thirst (polydipsia) is a hallmark sign that calcium levels are rising.
• Metallic Taste: Some patients report a distinct metallic or "off" taste in the mouth shortly after starting therapy.
• Headache: Mild to moderate headaches may occur during the initial titration phase.

• Anorexia: A loss of appetite or significant decrease in food intake.
• Weight Loss: Often secondary to gastrointestinal distress and loss of appetite.
• Somnolence: Excessive sleepiness or a feeling of lethargy.
• Muscle and Bone Pain: While calcitriol is used to treat bone disease, transient increases in bone or muscle pain can occur as mineral levels shift.
• Pruritus: Itching of the skin, which may be related to changes in calcium and phosphorus balance.

• Pancreatitis: Inflammation of the pancreas, characterized by severe abdominal pain radiating to the back.
• Cardiac Arrhythmias: High calcium levels can interfere with the electrical signals in the heart, leading to irregular heartbeats.
• Psychosis: Severe mental status changes, including hallucinations or extreme confusion, though this is usually seen only in cases of severe toxicity.
• Ectopic Calcification: The deposition of calcium in soft tissues, such as the heart valves, lungs, or skin.

> Warning: Stop taking Calcitriol and call your doctor immediately if you experience any of these symptoms of severe hypercalcemia.

• Severe Dehydration: Marked by extreme thirst, dark urine, and dizziness.
• Renal Colic: Intense pain in the side or back, which may indicate the formation of kidney stones (nephrolithiasis).
• Cardiac Palpitations: A feeling that the heart is skipping beats or racing, which can be a precursor to more dangerous arrhythmias.
• Mental Status Changes: Sudden confusion, agitation, or inability to stay awake.
• Severe Abdominal Pain: Could indicate pancreatitis or a bowel obstruction related to severe constipation.

Prolonged use of calcitriol without adequate monitoring can lead to chronic Vitamin D toxicity. This manifests as:

• Nephrocalcinosis: The buildup of calcium in the kidneys, which can lead to permanent kidney damage or failure.
• Vascular Calcification: Hardening of the arteries due to calcium deposits, increasing the risk of cardiovascular events like heart attack or stroke.
• Growth Retardation: In pediatric patients, chronic hypercalcemia can interfere with normal bone growth and development.
• Hypermagnesemia: If taken with magnesium-containing antacids, calcitriol can lead to dangerously high magnesium levels.

There are currently no FDA Black Box Warnings for calcitriol. However, the manufacturer provides a "strong warning" regarding the narrow therapeutic index and the necessity of frequent laboratory monitoring. The risk of hypercalcemia is considered the primary safety concern, and it is often stated that "the dose must be adjusted for each patient to avoid hypercalcemia."

Report any unusual symptoms to your healthcare provider. Early detection of rising calcium levels can prevent serious complications. Most side effects are reversible by simply holding the medication for a few days under medical supervision.

Calcitriol is a highly potent hormone that directly impacts the body's mineral balance. The most critical safety consideration is the prevention of hypercalcemia (high blood calcium). Patients must be aware that the margin between a therapeutic dose and a toxic dose is narrow. All patients receiving calcitriol must be willing to undergo regular blood testing and adhere strictly to dietary recommendations regarding calcium and phosphorus intake.

No FDA black box warnings for Calcitriol. However, clinical guidelines emphasize that hypercalcemia is a frequent and potentially dangerous complication of therapy.

• Hypercalcemia and Hypercalciuria: Calcitriol should not be started if the patient already has high calcium levels. If hypercalcemia develops during treatment, the drug must be stopped immediately until calcium levels return to normal. Chronic hypercalcemia can lead to generalized vascular calcification and nephrocalcinosis.
• Calcium-Phosphorus Product: In patients with chronic kidney disease, the product of serum calcium multiplied by serum phosphorus (Ca x P) should be monitored. If this product exceeds 55 mg²/dL², there is a high risk of calcium depositing in soft tissues (ectopic calcification).
• Concomitant Vitamin D Use: Patients should not take other Vitamin D supplements (like Vitamin D3 or D2) while taking calcitriol, as this significantly increases the risk of toxicity.
• Allergic Reactions: Although rare, hypersensitivity reactions (including anaphylaxis) have been reported. Patients with a known hypersensitivity to any Vitamin D analog should not use calcitriol.
• Digitalis Toxicity: Hypercalcemia of any cause can predispose patients to digitalis toxicity. If you take digoxin or other digitalis glycosides, your doctor must monitor you very closely.

Routine laboratory monitoring is the cornerstone of safe calcitriol therapy. At the start of treatment or during dose adjustments, the following should be checked at least twice weekly:

• Serum Calcium: The primary indicator of drug activity and safety.
• Serum Phosphorus: To ensure the Ca x P product remains within safe limits.
• Magnesium: Especially if the patient uses magnesium-containing medications.
• Alkaline Phosphatase: An indicator of bone turnover.
• Parathyroid Hormone (PTH): To assess the effectiveness of treatment in suppressing hyperparathyroidism.
• 24-Hour Urinary Calcium/Creatinine: In patients with hypoparathyroidism to prevent kidney stone formation.

Calcitriol generally does not affect the ability to drive or operate machinery. However, if you experience symptoms of hypercalcemia such as somnolence (sleepiness), dizziness, or confusion, you should avoid these activities until your symptoms resolve and your calcium levels are stabilized.

There is no direct chemical interaction between alcohol and calcitriol. However, excessive alcohol consumption can interfere with Vitamin D metabolism, worsen bone health, and increase the risk of dehydration. Dehydration can exacerbate the effects of hypercalcemia, so moderate or no alcohol use is generally recommended.

Calcitriol does not typically cause a withdrawal syndrome. However, stopping the medication abruptly in a patient with secondary hyperparathyroidism can lead to a rapid rebound in PTH levels and a subsequent drop in blood calcium (hypocalcemia). Any change in dosing or discontinuation must be managed by a healthcare provider who can monitor the transition.

> Important: Discuss all your medical conditions, including any history of kidney stones or heart disease, with your healthcare provider before starting Calcitriol.

• Vitamin D Compounds: Concurrent use of calcitriol with other Vitamin D analogs (e.g., ergocalciferol, cholecalciferol, paricalcitol, or doxercalciferol) is contraindicated. The additive effects can lead to rapid and severe hypercalcemia and Vitamin D toxicity.
• Calcium Supplements (High Dose): While some patients need calcium supplements, taking high doses of calcium alongside calcitriol without strict medical supervision can lead to the "Milk-Alkali Syndrome" and severe kidney damage.

• Digitalis Glycosides (Digoxin): Calcitriol increases serum calcium. High calcium levels sensitize the heart to the effects of digoxin, significantly increasing the risk of life-threatening cardiac arrhythmias. Close monitoring of the EKG and calcium levels is mandatory.
• Thiazide Diuretics (e.g., Hydrochlorothiazide): These drugs reduce the amount of calcium excreted in the urine. When combined with calcitriol, the risk of hypercalcemia is substantially increased because calcium is being absorbed more efficiently and excreted less efficiently.
• Magnesium-Containing Antacids/Laxatives: Calcitriol can increase the absorption of magnesium. In patients with chronic kidney disease, this can lead to hypermagnesemia, which causes muscle weakness and low blood pressure.

• Corticosteroids (e.g., Prednisone): Steroids can interfere with the calcium-absorbing effects of calcitriol. Patients on long-term steroid therapy may require higher doses of calcitriol to achieve the same effect.
• Bile Acid Sequestrants (e.g., Cholestyramine, Colestipol): These medications can bind to calcitriol in the gut and reduce its absorption. Calcitriol should be taken at least 1 hour before or 4 to 6 hours after these medications.
• Orlistat: This weight-loss medication reduces the absorption of fat-soluble vitamins, including calcitriol. It may decrease the efficacy of calcitriol therapy.
• Phenobarbital and Phenytoin: These anticonvulsants induce hepatic enzymes that may accelerate the metabolism of calcitriol, potentially reducing its blood levels and effectiveness.

• High-Calcium Foods: Dairy products, fortified juices, and leafy greens can significantly increase calcium levels when taking calcitriol. Patients must maintain a consistent (not necessarily low, but stable) intake of dietary calcium.
• Phosphate-Rich Foods: Since calcitriol increases phosphate absorption, patients with kidney disease must often limit foods like nuts, beans, dark sodas, and processed meats to prevent hyperphosphatemia.
• Grapefruit: Unlike many other drugs, calcitriol does not have a major interaction with grapefruit juice, as it is not primarily metabolized by the CYP3A4 enzyme.

• St. John's Wort: May potentially induce enzymes that metabolize calcitriol, though clinical data is limited.
• Calcium-Containing Herbs: Herbs like Alfalfa or Horsetail, which may contain minerals, should be used with caution.
• Vitamin A: High doses of Vitamin A can interfere with the bone-metabolizing effects of Vitamin D analogs.

Calcitriol therapy will alter several laboratory parameters as part of its therapeutic effect. It will typically increase serum calcium, increase serum phosphorus, and decrease serum alkaline phosphatase and PTH. It does not generally interfere with standard blood chemistry or hematology assays, but the physiological changes it causes must be correctly interpreted by the clinician.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. Even "natural" supplements can have profound effects on your mineral balance when combined with calcitriol.

Conditions where Calcitriol must NEVER be used include:

1. 1Hypercalcemia: If a patient has baseline serum calcium levels above the normal range (typically >10.5 mg/dL), calcitriol is strictly contraindicated. Administering the drug would further elevate calcium, leading to acute toxicity, cardiac arrest, or coma.
2. 2Vitamin D Toxicity: Patients with evidence of Vitamin D overdose (hypervitaminosis D) should not receive calcitriol, as it is the most potent form of the vitamin and will exacerbate the condition.
3. 3Hypersensitivity: A known allergy to calcitriol, other Vitamin D analogs (such as alfacalcidol or calcipotriene), or any of the inactive ingredients (like coconut oil or gelatin in the capsules) is an absolute contraindication.

These conditions require a careful risk-benefit analysis and intensive monitoring:

• Nephrolithiasis (Kidney Stones): Patients with a history of calcium-oxalate or calcium-phosphate stones are at higher risk for new stone formation. Calcitriol increases urinary calcium excretion, which can seed new stones.
• Severe Arteriosclerosis: In patients with advanced hardening of the arteries, there is a risk that elevated calcium levels will lead to further vascular calcification, worsening cardiovascular health.
• Severe Hepatic Disease: While the liver is not required for activation, severe liver disease can impair the absorption of fat-soluble vitamins and the production of Vitamin D Binding Protein, making dosing unpredictable.
• Sarcoidosis or Other Granulomatous Diseases: These conditions can involve the endogenous production of calcitriol by macrophages, which can lead to hypersensitivity to exogenous calcitriol and rapid hypercalcemia.

Patients who have experienced an allergic reaction to other forms of Vitamin D (such as Ergocalciferol or Cholecalciferol) or other analogs like Paricalcitol should be treated with extreme caution. While the chemical structures differ slightly, the potential for cross-reactivity exists. Symptoms of an allergic reaction may include skin rash, hives, swelling of the face or tongue, and difficulty breathing.

> Important: Your healthcare provider will evaluate your complete medical history, including your current blood chemistry and any history of heart or kidney disease, before prescribing Calcitriol.

Calcitriol is classified as FDA Pregnancy Category C. This means that animal reproduction studies have shown an adverse effect on the fetus (such as skeletal abnormalities when given in very high doses), but there are no adequate and well-controlled studies in humans. Calcitriol should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is crucial to monitor serum calcium levels more frequently during pregnancy, as maternal hypercalcemia can lead to hypocalcemia and seizures in the newborn. There is no evidence that calcitriol is used as a fertility treatment.

Calcitriol is known to be excreted into human breast milk. Because of the potential for serious adverse reactions in nursing infants (specifically hypercalcemia), a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. If a mother must take calcitriol while breastfeeding, the infant's serum calcium levels should be monitored closely by a pediatrician.

Calcitriol is approved for use in children for the treatment of hypoparathyroidism and renal osteodystrophy. However, safety and effectiveness in pediatric patients on dialysis have not been as extensively documented as in adults. The primary concern in children is the effect of calcium on the growth plates. Chronic hypercalcemia can lead to premature closure of the epiphyses (growth plates), resulting in stunted growth. Pediatric patients require frequent monitoring of serum calcium, phosphorus, and growth velocity.

Clinical studies of calcitriol did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently than younger subjects. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range. This reflects the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. Elderly patients are at a higher risk for falls and fractures if their calcium levels are not perfectly managed.

For patients with renal impairment (Stage 3-5 CKD), calcitriol is often the preferred therapy because it bypasses the need for renal 1-alpha-hydroxylation. However, these patients are at the highest risk for hyperphosphatemia. If phosphorus levels are not controlled with phosphate binders, the use of calcitriol can lead to a high Ca x P product and severe soft-tissue calcification. In patients on hemodialysis, IV calcitriol is often preferred over oral forms for better compliance and more predictable absorption.

No specific dose adjustment is required for patients with mild to moderate hepatic impairment. However, in patients with biliary cirrhosis or other obstructive liver diseases, the absorption of oral calcitriol may be significantly reduced due to a lack of bile salts in the intestine. In these cases, the IV formulation may be necessary to ensure therapeutic blood levels.

> Important: Special populations require individualized medical assessment. Always inform your doctor if you are pregnant, planning to become pregnant, or nursing before starting this medication.

Calcitriol is the most biologically active metabolite of vitamin D3. Its primary molecular target is the Vitamin D Receptor (VDR), a member of the steroid/thyroid hormone receptor superfamily. Upon binding, the calcitriol-VDR complex acts as a transcription factor. It increases the expression of the TRPV6 calcium channel and the calbindin-D9k protein in the intestinal epithelium, which facilitates the active transport of calcium from the gut lumen into the bloodstream. In the parathyroid glands, calcitriol binds to VDRs to inhibit the transcription of the pre-pro-PTH gene, directly reducing the production of parathyroid hormone. This is critical in preventing the "hungry bone" syndrome and secondary hyperparathyroidism seen in renal failure.

The pharmacodynamic effect of a single oral dose of calcitriol lasts about 3 to 5 days, although its plasma half-life is much shorter. This is because the changes in gene expression and protein synthesis (like calbindin) take time to reverse. The dose-response relationship is steep; small increases in dose can lead to significant increases in serum calcium. Tolerance does not typically develop; rather, the effect may become more pronounced over time as bone stores of calcium are replenished.

| Parameter | Value |

|---|---|

| Bioavailability | ~70% to 90% (Oral) |

| Protein Binding | 99.9% (to Vitamin D Binding Protein) |

| Half-life | 5 to 8 hours (Biological effect lasts 3-5 days) |

| Tmax | 3 to 6 hours |

| Metabolism | CYP24A1-mediated hydroxylation |

| Excretion | Fecal (Biliary) ~70-80%, Renal ~16% |

• Molecular Formula: C27H44O3
• Molecular Weight: 416.6 g/mol
• Solubility: Practically insoluble in water; soluble in organic solvents like ethanol and vegetable oils.
• Structure: A secosteroid consisting of three intact cholesterol rings and one broken ring (the B-ring), with hydroxyl groups at the 1, 3, and 25 positions.

Calcitriol is classified as a Vitamin D3 Analog and a Secosteroid Hormone. It is distinct from nutritional supplements like Cholecalciferol (D3) because it does not require activation by the kidneys. It is related to other synthetic analogs like Paricalcitol and Doxercalciferol, which are designed to have more selective effects on the parathyroid gland with less impact on intestinal calcium absorption.